EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Amy Meng  ¹     Chia-Hsiang Hsueh     Liyun Ni     Chohee Yun  ²     Cara Nelson    
¹ Gilead Sciences, Inc, Foster City, United States
² Gilead Sciences, Seoul, Korea, Democratic People's Republic of

Session
IBD: Clinical trials poster I

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)